Across TCGA pan-cancer cohorts, SFXN1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SFXN1 data layer compared with 29 for mass-spec protein and 7 for mass-spec protein.
The strongest signal is observed in rectum adenocarcinoma (READ), where higher SFXN1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SFXN1 expression acts as an unfavorable survival marker.
READ, PRAD, and LUAD are the cancer types where SFXN1 Mutation most reproducibly stratifies survival.